Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Treatment Outcomes and Dose Rate Effects Following Gamma Knife Stereotactic Radiosurgery for Vestibular Schwannomas.

Smith DR, Saadatmand HJ, Wu CC, Black PJ, Wuu YR, Lesser J, Horan M, Isaacson SR, Wang TJC, Sisti MB.

Neurosurgery. 2019 Jul 4. pii: nyz229. doi: 10.1093/neuros/nyz229. [Epub ahead of print]

PMID:
31270543
2.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2019 Jun 11:1-2. doi: 10.1017/S1092852919000932. [Epub ahead of print] No abstract available.

PMID:
31182180
3.

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Lyons KE, Pahwa R, Hermanowicz N, Davis T, Pagan F, Isaacson S.

Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 10.1080/17512433.2019.1623669. Epub 2019 Jun 13. Review.

PMID:
31159608
4.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T.

Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5.

PMID:
31122495
5.

Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.

Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-Ebo DM, Zhao P, Oh C.

Parkinsonism Relat Disord. 2019 Mar 30. pii: S1353-8020(19)30192-0. doi: 10.1016/j.parkreldis.2019.03.026. [Epub ahead of print]

6.

Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.

Isaacson SH, Boroojerdi B, Waln O, McGraw M, Kreitzman DL, Klos K, Revilla FJ, Heldman D, Phillips M, Terricabras D, Markowitz M, Woltering F, Carson S, Truong D.

Parkinsonism Relat Disord. 2019 Jan 28. pii: S1353-8020(19)30025-2. doi: 10.1016/j.parkreldis.2019.01.025. [Epub ahead of print]

PMID:
30948242
7.

Modeling Genetic Circuit Behavior in Transiently Transfected Mammalian Cells.

Wang J, Isaacson SA, Belta C.

ACS Synth Biol. 2019 Apr 19;8(4):697-707. doi: 10.1021/acssynbio.8b00166. Epub 2019 Mar 28.

PMID:
30884948
8.

Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners.

Henderson GE, Waltz M, Meagher K, Cadigan RJ, Jupimai T, Isaacson S, Ormsby NQ, Colby DJ, Kroon E, Phanuphak N, Ananworanich J, Peay HL.

J Int AIDS Soc. 2019 Mar;22(3):e25260. doi: 10.1002/jia2.25260.

9.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.

PMID:
30663606
10.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359.

PMID:
30588905
11.

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.

Pahwa R, Isaacson S, Jimenez-Shaheed J, Malaty IA, Deik A, Johnson R, Patni R.

Parkinsonism Relat Disord. 2019 Mar;60:118-125. doi: 10.1016/j.parkreldis.2018.09.005. Epub 2018 Sep 5.

12.

Using Unentangled Oligomers To Toughen Materials.

Isaacson SG, Matsuda Y, Lionti K, Frot T, Volksen W, Dauskardt RH, Dubois G.

ACS Appl Mater Interfaces. 2018 Aug 22;10(33):27549-27554. doi: 10.1021/acsami.8b03050. Epub 2018 Aug 9.

PMID:
30074761
13.

Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel.

Pahwa R, Isaacson SH, Torres-Russotto D, Nahab FB, Lynch PM, Kotschet KE.

Expert Rev Neurother. 2018 Aug;18(8):669-680. doi: 10.1080/14737175.2018.1503948. Epub 2018 Jul 26.

PMID:
30032695
14.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018 Oct 1;75(10):1206-1214. doi: 10.1001/jamaneurol.2018.1487.

15.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

16.

The JFK BIG study: the impact of LSVT BIG® on dual task walking and mobility in persons with Parkinson's disease.

Isaacson S, O'Brien A, Lazaro JD, Ray A, Fluet G.

J Phys Ther Sci. 2018 Apr;30(4):636-641. doi: 10.1589/jpts.30.636. Epub 2018 Apr 20.

17.

Orbital Radiotherapy Combined With Corticosteroid Treatment for Thyroid Eye Disease-Compressive Optic Neuropathy.

Gold KG, Scofield S, Isaacson SR, Stewart MW, Kazim M.

Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):172-177. doi: 10.1097/IOP.0000000000001003.

PMID:
29517594
18.

Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases.

Tai CH, Wu CC, Hwang ME, Saraf A, Grubb C, Jani A, Lapa ME, Andrews JIS, Isaacson SR, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Cheng SK, Connolly EP, Wang TJ.

CNS Oncol. 2018 Jan;7(1):25-34. doi: 10.2217/cns-2017-0023. Epub 2018 Feb 2.

19.

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W.

Int J Neurosci. 2018 Jul;128(7):619-626. doi: 10.1080/00207454.2017.1406935. Epub 2018 Jan 17.

PMID:
29343142
20.

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC.

J Neurooncol. 2018 Apr;137(2):303-311. doi: 10.1007/s11060-017-2718-z. Epub 2017 Dec 20.

PMID:
29264835
21.

Local control and overall survival for adjuvant stereotactic radiosurgery in patients with residual or recurrent disease.

Nanda T, Yaeh A, Wu CC, Jani A, Saad S, Qureshi YH, Cauley KA, Lesser J, Cheng SK, Isaacson SR, Sisti MB, Bruce JN, McKhann GM, Sheth SA, Lassman AB, Wang TJC.

J Neurooncol. 2018 Jan;136(2):281-287. doi: 10.1007/s11060-017-2651-1. Epub 2017 Nov 23.

PMID:
29170908
22.

Dense Vertically Aligned Copper Nanowire Composites as High Performance Thermal Interface Materials.

Barako MT, Isaacson SG, Lian F, Pop E, Dauskardt RH, Goodson KE, Tice J.

ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42067-42074. doi: 10.1021/acsami.7b12313. Epub 2017 Nov 20.

PMID:
29119783
23.

Synthesis of Polyimides in Molecular-Scale Confinement for Low-Density Hybrid Nanocomposites.

Isaacson SG, Fostvedt JI, Koerner H, Baur JW, Lionti K, Volksen W, Dubois G, Dauskardt RH.

Nano Lett. 2017 Nov 8;17(11):7040-7044. doi: 10.1021/acs.nanolett.7b03725. Epub 2017 Oct 17.

PMID:
28991490
24.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.

25.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ.

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.

26.

Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.

Saraf A, Grubb CS, Hwang ME, Tai CH, Wu CC, Jani A, Lapa ME, Andrews JIS, Vanderkelen S, Isaacson SR, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Cheng SK, Connolly EP, Wang TJC.

J Neurooncol. 2017 Sep;134(2):453-463. doi: 10.1007/s11060-017-2549-y. Epub 2017 Jul 3.

PMID:
28674973
27.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.

28.

Gamma Knife treatment of recurrent CNS metastases of pancreatic origin: a case report and review of the literature.

Perni S, Wang TJ, Lesser J, Mandigo C, Isaacson SR, Horowitz DP.

CNS Oncol. 2017 Apr;6(2):111-118. doi: 10.2217/cns-2016-0026. Review.

29.

Whole-brain Irradiation Field Design: A Comparison of Parotid Dose.

Wu CC, Wuu YR, Jani A, Saraf A, Tai CH, Lapa ME, Andrew JIS, Tiwari A, Saadatmand HJ, Isaacson SR, Cheng SK, Wang TJC.

Med Dosim. 2017 Summer;42(2):145-149. doi: 10.1016/j.meddos.2017.02.006. Epub 2017 May 4.

PMID:
28479012
30.

Biophysical assay for tethered signaling reactions reveals tether-controlled activity for the phosphatase SHP-1.

Goyette J, Salas CS, Coker-Gordon N, Bridge M, Isaacson SA, Allard J, Dushek O.

Sci Adv. 2017 Mar 24;3(3):e1601692. doi: 10.1126/sciadv.1601692. eCollection 2017 Mar.

31.

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F.

Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78-83. doi: 10.1002/mdc3.12350. Epub 2016 May 25.

32.

Efficacy and outcomes of facial nerve-sparing treatment approach to cerebellopontine angle meningiomas.

D'Amico RS, Banu MA, Petridis P, Bercow AS, Malone H, Praver M, Wang TJC, Isaacson SR, Sisti MB.

J Neurosurg. 2017 Dec;127(6):1231-1241. doi: 10.3171/2016.10.JNS161982. Epub 2017 Feb 10.

PMID:
28186449
33.

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H.

J Neurol. 2017 Aug;264(8):1567-1582. doi: 10.1007/s00415-016-8375-x. Epub 2017 Jan 3. Review.

34.

Uniform asymptotic approximation of diffusion to a small target: Generalized reaction models.

Isaacson SA, Mauro AJ, Newby J.

Phys Rev E. 2016 Oct;94(4-1):042414. Epub 2016 Oct 18.

PMID:
27841549
35.

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.

Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, Marek K, Pahwa R, Russell DS, Seibyl J.

Expert Rev Neurother. 2017 Mar;17(3):219-225. doi: 10.1080/14737175.2017.1256205. Epub 2016 Nov 23. Review.

PMID:
27813429
36.

Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).

Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.

J Parkinsons Dis. 2016 Oct 19;6(4):751-759. doi: 10.3233/JPD-160860.

PMID:
27636856
37.

Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.

J Am Soc Hypertens. 2016 Oct;10(10):755-762. doi: 10.1016/j.jash.2016.07.010. Epub 2016 Aug 4.

38.

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.

Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A.

Mov Disord. 2016 Sep;31(9):1366-72. doi: 10.1002/mds.26697. Epub 2016 Jul 19.

PMID:
27430123
39.

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.

Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH.

Clin Neuropharmacol. 2016 Sep-Oct;39(5):220-6. doi: 10.1097/WNF.0000000000000168.

40.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
41.

Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):306-314. doi: 10.1016/j.prro.2015.12.001. Epub 2015 Dec 4.

PMID:
26952813
42.

Managed care approach to the treatment of neurogenic orthostatic hypotension.

Isaacson SH.

Am J Manag Care. 2015 Oct;21(13 Suppl):s258-68. Review.

43.

A Modern Radiotherapy Series of Survival in Hispanic Patients with Glioblastoma.

Wu CC, Wang TJ, Jani A, Estrada JP, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb CS, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, McKhann GM 2nd.

World Neurosurg. 2016 Apr;88:260-9. doi: 10.1016/j.wneu.2015.12.081. Epub 2015 Dec 31.

PMID:
26746331
44.

Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.

Grubb CS, Jani A, Wu CC, Saad S, Qureshi YH, Nanda T, Yaeh A, Rozenblat T, Sisti MB, Bruce JN, McKhann GM 2nd, Sheth SA, Lesser J, Cheng SK, Isaacson SR, Lassman AB, Connolly EP, Wang TJ.

J Neurooncol. 2016 Mar;127(1):103-10. doi: 10.1007/s11060-015-2014-8. Epub 2015 Nov 28.

PMID:
26615564
45.

Fundamental limits of material toughening in molecularly confined polymers.

Isaacson SG, Lionti K, Volksen W, Magbitang TP, Matsuda Y, Dauskardt RH, Dubois G.

Nat Mater. 2016 Mar;15(3):294-8. doi: 10.1038/nmat4475. Epub 2015 Nov 16.

PMID:
26569473
46.

Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.

Wang TJ, Jani A, Estrada JP, Ung TH, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Isaacson SR, Cheng SK, McKhann GM 2nd, Bruce JN, Lassman AB, Sisti MB.

Neurosurgery. 2016 May;78(5):676-82. doi: 10.1227/NEU.0000000000001036.

PMID:
26440447
47.

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ.

J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1.

PMID:
26239690
48.

Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery.

Yaeh A, Nanda T, Jani A, Rozenblat T, Qureshi Y, Saad S, Lesser J, Lassman AB, Isaacson SR, Sisti MB, Bruce JN, McKhann GM 2nd, Wang TJ.

J Neurooncol. 2015 Sep;124(3):507-14. doi: 10.1007/s11060-015-1871-5. Epub 2015 Aug 2.

PMID:
26233247
49.

Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.

Trenkwalder C, Chaudhuri KR, García Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Döring F, Henriksen T, Sesar Á, Poewe W; Expert Consensus Group for Use of Apomorphine in Parkinson's Disease, Baker M, Ceballos-Baumann A, Deuschl G, Drapier S, Ebersbach G, Evans A, Fernandez H, Isaacson S, van Laar T, Lees A, Lewis S, Martínez Castrillo JC, Martinez-Martin P, Odin P, O'Sullivan J, Tagaris G, Wenzel K.

Parkinsonism Relat Disord. 2015 Sep;21(9):1023-30. doi: 10.1016/j.parkreldis.2015.06.012. Epub 2015 Jun 17. Review.

PMID:
26189414
50.

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?

Wang TJ, Saad S, Qureshi YH, Jani A, Nanda T, Yaeh AM, Rozenblat T, Sisti MB, Bruce JN, McKhann GM, Lesser J, Halmos B, Stoopler MB, Lassman AB, Cheng SK, Isaacson SR.

Neuro Oncol. 2015 Jul;17(7):1022-8. doi: 10.1093/neuonc/nov043. Epub 2015 Apr 24.

Supplemental Content

Loading ...
Support Center